{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:01:36Z","timestamp":1792551696433,"version":"4.5.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["148363"],"award-info":[{"award-number":["148363"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["950-231335"],"award-info":[{"award-number":["950-231335"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jlr.2021.100130","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T08:43:06Z","timestamp":1633164186000},"page":"100130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-9342","authenticated-orcid":false,"given":"Nabil G.","family":"Seidah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2021.100130_bib1","series-title":"Molecular Neuroendocrinology: From Genome to Physiology","first-page":"171","article-title":"Posttranslational processing of secretory proteins","author":"Seidah","year":"2016"},{"key":"10.1016\/j.jlr.2021.100130_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-8993(99)01909-5","article-title":"Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides","volume":"848","author":"Seidah","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.jlr.2021.100130_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61779-204-5_1","article-title":"On the discovery of precursor processing","volume":"768","author":"Steiner","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fendo.2013.00148","article-title":"How the prohormone theory solved two important controversies in hormonal and neural peptide biosynthesis","volume":"4","author":"Chretien","year":"2013","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jlr.2021.100130_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrm934","article-title":"Furin at the cutting edge: from protein traffic to embryogenesis and disease","volume":"3","author":"Thomas","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jlr.2021.100130_bib7","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.R113.481549","article-title":"The multifaceted proprotein convertases: their unique, redundant, complementary and opposite functions","volume":"288","author":"Seidah","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jlr.2021.100130_bib9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0092-8674(84)90442-2","article-title":"Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro-alpha-factor","volume":"37","author":"Julius","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0006-291X(88)80832-5","article-title":"Yeast KEX2 genes encodes an endopeptidase homologous to subtilisin-like serine proteases","volume":"156","author":"Mizuno","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jlr.2021.100130_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pro.5560060301","article-title":"Subtilases: the superfamily of subtilisin-like serine proteases","volume":"6","author":"Siezen","year":"1997","journal-title":"Protein Sci."},{"key":"10.1016\/j.jlr.2021.100130_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/333093a0","article-title":"Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic beta cell via two distinct site-specific endopeptidases","volume":"333","author":"Davidson","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2021.100130_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/dna.1990.9.415","article-title":"cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products: tissue-specific mRNAs encoding candidates for pro- hormone processing proteinases","volume":"9","author":"Seidah","year":"1990","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/dna.1992.11.283","article-title":"The cDNA sequence of the human pro-hormone and pro-protein convertase PC1","volume":"11","author":"Seidah","year":"1992","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib15","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0021-9258(19)39721-2","article-title":"Identification of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2","volume":"265","author":"Smeekens","year":"1990","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ng0797-303","article-title":"Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene","volume":"16","author":"Jackson","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1172\/JCI200318784","article-title":"Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency","volume":"112","author":"Jackson","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100130_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2337\/db11-0305","article-title":"Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity","volume":"61","author":"Creemers","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jlr.2021.100130_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.molmet.2016.12.002","article-title":"Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolism","volume":"6","author":"Loffler","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jlr.2021.100130_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1172\/JCI88648","article-title":"Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome","volume":"127","author":"Burnett","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100130_bib21","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1093\/nar\/17.17.7101","article-title":"Nucleotide sequence analysis of the human fur gene","volume":"17","author":"van den Ouweland","year":"1989","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jlr.2021.100130_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00429896","article-title":"Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes","volume":"14","author":"Van de Ven","year":"1990","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib23","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.0800340105","article-title":"Role of furin in granular acidification in the endocrine pancreas: identification of the V-ATPase subunit Ac45 as a candidate substrate","volume":"105","author":"Louagie","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1096\/fj.02-0831rev","article-title":"Curbing activation: proprotein convertases in homeostasis and pathology","volume":"17","author":"Taylor","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.jlr.2021.100130_bib25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/v13071229","article-title":"How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread?","volume":"13","author":"Seidah","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jlr.2021.100130_bib26","article-title":"Implications of Spike-glycoprotein processing at S1\/S2 by Furin, at S2\u2019 by Furin and\/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2","author":"Essalmani","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.jlr.2021.100130_bib27","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1101\/gad.16738711","article-title":"The microenvironment patterns the pluripotent mouse epiblast through paracrine Furin and Pace4 proteolytic activities","volume":"25","author":"Mesnard","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.jlr.2021.100130_bib28","doi-asserted-by":"crossref","first-page":"27157","DOI":"10.1074\/jbc.M109.028506","article-title":"Site-specific cleavage of BMP4 by furin, PC6, and PC7","volume":"284","author":"Nelsen","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib29","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib30","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In\u00a0vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1101\/gad.14.9.1146","article-title":"SPC4\/PACE4 regulates a TGFbeta signaling network during axis formation","volume":"14","author":"Constam","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.jlr.2021.100130_bib32","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1101\/gad.479408","article-title":"VACTERL\/caudal regression\/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5","volume":"22","author":"Szumska","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.jlr.2021.100130_bib33","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1128\/MCB.06331-11","article-title":"Loss of endothelial furin leads to cardiac malformation and early postnatal death","volume":"32","author":"Kim","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib34","series-title":"Handbook of the Biologically Active peptides","first-page":"1821","article-title":"Proprotein convertases SKI-1\/S1P and PCSK9","author":"Seidah","year":"2012"},{"key":"10.1016\/j.jlr.2021.100130_bib35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1073\/pnas.96.4.1321","article-title":"Mammalian subtilisin\/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization","volume":"96","author":"Seidah","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib36","doi-asserted-by":"crossref","first-page":"23471","DOI":"10.1074\/jbc.M513675200","article-title":"The proprotein convertase SKI-1\/S1P: in\u00a0vitro analysis of lassa virus glycoprotein-derived substrates and ex\u00a0vivo validation of irreversible peptide inhibitors","volume":"281","author":"Pasquato","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1097-2765(00)80150-1","article-title":"Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells","volume":"2","author":"Sakai","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib38","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1097-2765(00)00133-7","article-title":"ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs","volume":"6","author":"Ye","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000151723","article-title":"Potential role of proprotein convertase SKI-1 in the mineralization of primary bone","volume":"189","author":"Gorski","year":"2009","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.jlr.2021.100130_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.1205677","article-title":"A\u00a0key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism","volume":"333","author":"Marschner","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jlr.2021.100130_bib41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jlr.2021.100130_bib44","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib45","doi-asserted-by":"crossref","first-page":"33745","DOI":"10.1074\/jbc.M112.399725","article-title":"Loss- and gain-of-function PCSK9 variants: clevage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation","volume":"287","author":"Benjannet","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072113","article-title":"PCSK9 prosegment chimera as novel inhibitors of LDLR degradation","volume":"8","author":"Luna Saavedra","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2021.100130_bib47","doi-asserted-by":"crossref","first-page":"158968","DOI":"10.1016\/j.bbalip.2021.158968","article-title":"Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice","volume":"1866","author":"Peyot","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jlr.2021.100130_bib48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2021.100130_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41586-018-0590-4","article-title":"Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris","volume":"562","author":"Consortium","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2021.100130_bib50","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1086\/302370","article-title":"A\u00a0third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32","volume":"64","author":"Varret","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","article-title":"Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred","volume":"20","author":"Hunt","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A\u00a0mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib54","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib55","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib56","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib57","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib58","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1073\/pnas.1534923100","article-title":"Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes","volume":"100","author":"Horton","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib59","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2005.04.006","article-title":"Dual regulation of the LDL receptor--some clarity and new questions","volume":"1","author":"Attie","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2021.100130_bib61","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib62","doi-asserted-by":"crossref","first-page":"33913","DOI":"10.1074\/jbc.274.48.33913","article-title":"The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In\u00a0vitro and ex\u00a0vivo assessment of their efficacy and selectivity","volume":"274","author":"Zhong","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib64","doi-asserted-by":"crossref","first-page":"13607","DOI":"10.1073\/pnas.201524598","article-title":"Decreased lipid synthesis in livers of mice with disrupted site-1 protease gene","volume":"98","author":"Yang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib65","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100130_bib68","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jlr.2021.100130_bib70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Cameron","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jlr.2021.100130_bib71","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib72","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1194\/jlr.M400396-JLR200","article-title":"Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells","volume":"46","author":"Lalanne","year":"2005","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib73","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib74","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1194\/jlr.M800049-JLR200","article-title":"Functional analysis of sites within PCSK9 responsible for hypercholesterolemia","volume":"49","author":"Pandit","year":"2008","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib75","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1194\/jlr.M300448-JLR200","article-title":"Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation","volume":"45","author":"Tremblay","year":"2004","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib76","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","article-title":"Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production","volume":"25","author":"Millar","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib77","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"PCSK9-dependent LDL receptor regulation: effects of pH and LDL","volume":"282","author":"Fisher","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1194\/jlr.M087189","article-title":"Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake","volume":"60","author":"Galvan","year":"2019","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib79","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib80","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.jlr.2021.100130_bib82","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib83","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1091\/mbc.11.6.1947","article-title":"The Kex2p proregion is essential for the biosynthesis of an active enzyme and requires a C-terminal basic residue for its function","volume":"11","author":"Lesage","year":"2000","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib84","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jlr.2021.100130_bib86","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib87","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib88","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100130_bib89","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.jlr.2021.100130_bib90","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2121-8-9","article-title":"Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly","volume":"8","author":"Holla","year":"2007","journal-title":"BMC. Cell Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib92","doi-asserted-by":"crossref","first-page":"16659","DOI":"10.1074\/jbc.M116.717736","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation","volume":"291","author":"Weider","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib93","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1515\/hsz-2018-0194","article-title":"A\u00a0single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice","volume":"399","author":"Essalmani","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib94","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A\u00a0proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jmb.2013.11.011","article-title":"An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in\u00a0vivo","volume":"426","author":"Schiele","year":"2014","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib96","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50 Suppl","author":"Horton","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib97","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.0806312105","article-title":"Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib98","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1194\/jlr.M018093","article-title":"Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors","volume":"52","author":"Holla","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib99","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.jlr.2021.100130_bib100","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.1074\/jbc.M115.647180","article-title":"Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9-mediated low density lipoprotein receptor degradation but interact with each other","volume":"290","author":"Butkinaree","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","article-title":"Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9","volume":"41","author":"Jang","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100130_bib102","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/ATVBAHA.119.313247","article-title":"Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor)","volume":"39","author":"Ben Djoudi Ouadda","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib103","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of PCSK9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100130_bib104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/labinvest.2017.47","article-title":"Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation","volume":"97","author":"Kumar","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.jlr.2021.100130_bib106","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jlr.2021.100130_bib107","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100130_bib108","doi-asserted-by":"crossref","first-page":"603910","DOI":"10.3389\/fphys.2021.603910","article-title":"New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects","volume":"12","author":"Ying","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jlr.2021.100130_bib109","article-title":"The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol","volume":"2017","author":"Seidah","year":"2017","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"10.1016\/j.jlr.2021.100130_bib110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100130_bib111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11883-017-0684-8","article-title":"PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies","volume":"19","author":"El Khoury","year":"2017","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib112","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A\u00a0proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100130_bib113","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.jlr.2021.100130_bib114","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2021.100130_bib115","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100130_bib116","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","article-title":"Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Hovingh","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100130_bib117","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A\u00a0highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100130_bib118","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jlr.2021.100130_bib119","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jacc.2021.01.008","article-title":"Inclisiran: a game changer in a changing game?","volume":"77","author":"Nambi","year":"2021","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100130_bib120","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-021-00477-7","article-title":"A\u00a0critical review of the efficacy and safety of inclisiran","author":"Hardy","year":"2021","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.jlr.2021.100130_bib121","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cvr\/cvz003","article-title":"Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies","volume":"115","author":"Seidah","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jlr.2021.100130_bib122","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40119-020-00191-6","article-title":"Vaccines targeting PSCK9 for the treatment of hyperlipidemia","volume":"9","author":"Toth","year":"2020","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.jlr.2021.100130_bib123","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2021.100130_bib124","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1172\/JCI137536","article-title":"Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes","volume":"130","author":"Gan","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100130_bib125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fphar.2013.00119","article-title":"The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics","volume":"4","author":"Cruz","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jlr.2021.100130_bib127","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.jlr.2021.100130_bib128","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.neo.2021.07.007","article-title":"Proprotein convertase subtilisin\/kexin type 9 is required for Ahnak-mediated metastasis of melanoma into lung epithelial cells","volume":"23","author":"Suh","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.jlr.2021.100130_bib129","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","article-title":"Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line","volume":"291","author":"Ruscica","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib130","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jlr.2021.100130_bib131","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","article-title":"A\u00a0Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2021.100130_bib132","doi-asserted-by":"crossref","first-page":"188581","DOI":"10.1016\/j.bbcan.2021.188581","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): a potential multifaceted player in cancer","volume":"1876","author":"Bhattacharya","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jlr.2021.100130_bib133","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12876-015-0371-6","article-title":"Decreased PCSK9 expression in human hepatocellular carcinoma","volume":"15","author":"Bhat","year":"2015","journal-title":"BMC. Gastroenterol."},{"key":"10.1016\/j.jlr.2021.100130_bib134","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.jlr.2021.100130_bib135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2021.100130_bib136","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A\u00a0decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2021.100130_bib137","doi-asserted-by":"crossref","DOI":"10.2174\/1381612827999210111182030","article-title":"The state of the problem of achieving extremely low LDL levels","author":"Korneva","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jlr.2021.100130_bib138","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacl.2017.04.001","article-title":"Can iPCSK9-induced hypocholesterolemia starve cancer cells?","volume":"11","author":"Gangloff","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100130_bib139","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1111\/febs.15212","article-title":"Proprotein convertase 7 (PCSK7) reduces apoA-V levels","volume":"287","author":"Ashraf","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.jlr.2021.100130_bib140","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/13543776.2016.1206080","article-title":"Proprotein convertase subtilisin\/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","volume":"26","author":"Elbitar","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jlr.2021.100130_bib141","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1177\/2047487317708890","article-title":"New data on familial hypercholesterolaemia and acute coronary syndromes: the promise of PCSK9 monoclonal antibodies in the light of recent clinical trials","volume":"24","author":"Ellis","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.jlr.2021.100130_bib142","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-019-0778-6","article-title":"Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease","volume":"21","author":"Dixon","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib143","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","article-title":"Role of PCSK9 beyond liver involvement","volume":"26","author":"Cariou","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100130_bib144","doi-asserted-by":"crossref","first-page":"598649","DOI":"10.3389\/fphys.2020.598649","article-title":"Coming back to physiology: extra hepatic functions of proprotein convertase subtilisin\/kexin type 9","volume":"11","author":"Schl\u00fcter","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jlr.2021.100130_bib145","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.jlr.2021.100096","article-title":"PCSK9 is not secreted from mature differentiated intestinal cells","volume":"62","author":"Fran\u00e7ois","year":"2021","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100130_bib146","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","article-title":"Circulating rather than intestinal PCSK9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice","volume":"40","author":"Gar\u00e7on","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100130_bib147","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2021.03.044","article-title":"Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function","volume":"326","author":"Ramin-Mangata","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100130_bib148","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/febs.15036","article-title":"Functional analysis of natural PCSK9 mutants in modern and archaic humans","volume":"287","author":"Mikaeeli","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.jlr.2021.100130_bib149","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","article-title":"The proprotein convertase subtilisin\/kexin type 9-resistant R410S low density lipoprotein receptor mutation: a novel mechanism causing familial hypercholesterolemia","volume":"292","author":"Susan-Resiga","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib150","article-title":"Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placenta","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2021.100130_bib151","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jlr.2021.100130_bib152","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.jlr.2021.100130_bib153","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1038\/s41598-018-28777-0","article-title":"Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor","volume":"8","author":"Grin","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib154","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1038\/s41598-019-46745-0","article-title":"Reduced proprotein convertase subtilisin\/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients","volume":"9","author":"Leung","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2021.100130_bib155","first-page":"2687692","article-title":"PCSK9: a potential therapeutic target for sepsis","volume":"2020","author":"Yuan","year":"2020","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.jlr.2021.100130_bib156","article-title":"PCSK 9: a link between inflammation and atherosclerosis","author":"Patriki","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jlr.2021.100130_bib157","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.3390\/ijms22137193","article-title":"Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways","volume":"22","author":"Cammisotto","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227521001127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227521001127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T10:07:34Z","timestamp":1645092454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227521001127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":157,"alternative-id":["S0022227521001127"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2021.100130","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2021.100130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100130"}}